<DOC>
	<DOC>NCT02246881</DOC>
	<brief_summary>The main objective of the study is to compare the pharmacokinetics of Optivate速 with the subject's current FVIII concentrate when given as a bolus dose of 50IU/kg. The secondary objective is to compare the first and second pharmacokinetic assessments on Optivate速 (and recovery if a subject changes batch) to evaluate Optivate速 in terms of clinical tolerance and safety.</brief_summary>
	<brief_title>A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate速 in Haemophilia A.</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Previously treated subjects with severe Haemophilia A (&lt;2% basal FVIII activity) without inhibitor to Factor VIII, at least 12 years of age, currently receiving FVIII concentrate and with more than 20 exposure days.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>